GlaxoSmithKline Stock News

Ledyard National Bank boosted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 3.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 9,651 shares of the pharmaceutical companys stock after buying an additional 300 shares during the period. Ledyard National Banks holdings in GlaxoSmithKline were worth $369,000 as of its most recent SEC []

Preclinical data demonstrates sotrovimab retains activity against key Omicron mutations Related Stocks: GSK , LSE:GSK , AZN , LLY , REGN , VIR , SNY ,

A clinical trial is a research investigation in which individuals can participate. The intent of a clinical trial is to investigate the efficacy of a treatment, medication, experimental drug or instrument. Clinical trials in the field of neurology constitute neurology

Anti-obesity therapies are drugs that help people lose or maintain their weight. These drugs affect one of the body''s most basic functions, weight control, by affecting appetite or calorie absorption. Diet and physical activity remain the main therapeutic strategies for

Increasing prevalence of skin infections such as eczema and psoriasis, as well as minor diseases such as acne, is one of the factors responsible for the growth of the topical drug delivery market. Preference for drug delivery through the skin

The Latest survey report on Global DNA Vaccines Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, DNA Vaccines organizations have the dual challenge of increasing interoperability to improve clinical

British drugmaker GlaxoSmithKline has claimed that early laboratory tests show that its antibody drug against Covid-19 is effective against the new super mutant Omicron variant.

London, Dec 3 (IANS) British drugmaker GlaxoSmithKline has claimed that early laboratory tests show that its antibody drug against Covid-19 is effective against the new super mutant Omicron variant. GSK developed Sotrovimab, with US partner Vir Biotechnology, a monoclonal antibody based on the natural antibodies humans already make. In clinical trials, sotrovimab was shown to [] The post GSKs early data shows Covid antibody drug effective against Omicron appeared first on Buziness Bytes .

Preclinical data showed that sotrovimab "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline said in a statement.

Pfizer Jab & GSK''s Antibody Drug Are Effective Against Omicron After teasing various aspects of his plan to protect Americans from the omciron variant (which is arriving at the start of the latest ''winter wave'') while the CDC quietly collects names of travelers who recently visited southern Africa, President Joe Biden is preparing to share his plan, which will impose tighter restrictions on foreign travelers while extending a mask mandate and (potentially) double down on vaccine restrictions for American workers (even as multiple federal judges have rejected the mandate). Biden''s comments are expected later on Thursday, but during the early hours of the US session, Germany''s outgoing Chancellor Angela Merkel and her successor, Olaf Scholz, agreed on a plan to effectively mandate vaccinations by imposing stringent restrictions on Germans who haven''t voluntarily gotten the jab. As governments scramble to use omicron as an excuse to crack down on the unvaccinated, makers of vaccines and COVID remedies have continued to share data about their products'' efficacy at combating the omicron variant.

A Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology was effective against the Omicron variant in early laboratory studies.

This fool assesses GlaxoSmithKline stock for his long-term portfolio after a new Covid drug received the green light for use in the UK. The post Is GlaxoSmithKline stock the best Covid pharma pick? appeared first on The Motley Fool UK .

Futures Rebound Fizzles On Slowing iPhone Demand, Omicron Fears U.S. index futures regained some ground alongside Asian markets while European stocks slumped to session lows in a delayed response to yesterday''s late Omicron-driven US selloff, as markets remained volatile following the biggest two-day plunge in more than a year, spurred by concern about the omicron coronavirus variant and Federal Reserve tightening. Investors await data for unemployment claims, as well as earnings from companies including Dollar General and Kroger. Tech is the weakest sector, dropping in sympathy after Apple warned its suppliers of slowing iPhone demand. Nasdaq futures pared earlier gains of up to 0.8% to trade down 0.1% while S&P futures are only 0.2% higher after rising as much as 0.9%. While the knee-jerk reaction of stock investors may continue to be to take profits before the end of the year, there is plenty of liquidity available to drive stock prices higher as dip-buyers enter the market , Ed Yardeni wrote in a note.

Pharma giant GlaxoSmithKline said on Thursday that an antibody cocktail it developed with a U.S. biotech company has proven in lab testing to be effective against the Omicron coronavirus variant.

GlaxoSmithKline (GSK) has said that its coronavirus drug called sotrovimab is effective against the Omicron variant.